Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA (FRA:MRK) in a research report sent to investors on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

MRK has been the subject of several other reports. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the stock a buy rating in a research note on Friday, September 6th. DZ Bank reissued a buy rating on shares of Merck KGaA in a research note on Wednesday, August 14th. Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a buy rating in a research report on Monday, June 17th. Barclays set a €82.00 ($95.35) price objective on Merck KGaA and gave the stock a sell rating in a research report on Wednesday, August 14th. Finally, UBS Group set a €99.00 ($115.12) price objective on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of €100.94 ($117.38).

MRK traded up €1.66 ($1.93) on Thursday, hitting €99.02 ($115.14). 739,433 shares of the company were exchanged. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72). The firm has a 50-day moving average price of €94.72 and a two-hundred day moving average price of €94.64.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: Buyback

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.